PPAR delta: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension
PPAR delta: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension
复制标题
PPAR δ：代谢性高血压的潜在治疗靶点
DOI：
10.1155/2019/7809216
复制
发表时间：
2019
影响因子：
1.9
通讯作者：
Yan Zhencheng
中科院分区：
文献类型：
--
作者：
Jiang Yanli;Li Qiang;Jia Mengxiao;Yan Zhencheng
高血压及其相关的心血管疾病一直是公共卫生的主要风险。多种代谢危险因素可导致血管功能障碍和血管病变，代谢紊乱引起的高血压被定义为代谢性高血压。核受体亚家族的成员，过氧化物酶体增殖物激活受体（PPARs），被发现是代谢和血管功能的关键调节因子。我们提供了关于亚型PPARδ在代谢和血管功能调节中的作用及其干预对代谢性高血压管理的影响的最新知识。我们希望能为代谢性高血压及其主要并发症的更有效治疗提供一些见解。
High blood pressure and its associated cardiovascular diseases have been major risks for public health. Multiple metabolic risk factors can cause the vascular dysfunction and vascular lesion, and the hypertension due to metabolic disturbances was defined as metabolic hypertension. The members of a subfamily of the nuclear receptors, peroxisome proliferator‐activated receptors (PPARs), were found to be key regulators of metabolism and vascular function. We provide up‐to‐date knowledge on the role of subtype PPARδin the regulation of metabolism and vascular function and the effect of its intervention on the metabolic hypertension management. We hope to give some insights into the development of more effective treatments of metabolic hypertension and its main complications.